Article,
Personalised therapy in follicular lymphoma – is the dial turning?
Contributors
Linton, Kim M
0000-0002-3294-1548
(Corresponding author)
[1]
[2]
Specht, Lena K
0000-0002-6902-2190
[3]
[4]
Kimby, Eva K
0000-0003-3078-6131
[8]
De Jong, Daphne D
0000-0002-9725-4060
[9]
Cottereau, Anne-Ségolène
0000-0002-4805-4564
[11]
Casulo, Carla
0000-0003-4998-9932
[12]
Sarkozy, Clémentine
0000-0002-1942-9304
[13]
Okosun, Jessica
0000-0001-6021-5044
[14]
Affiliations
- [1] Manchester Cancer Research Centre [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [2] The Christie NHS Foundation Trust [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [3] Rigshospitalet [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
- [4] University of Copenhagen [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD];
- [5] Centro de Helmatología Pavlovsky, Medical Director, Buenos Aires, Argentina [NORA names: Argentina; America, South];
(... more)
Abstract
Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%-25% of all new non-Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes includes high-risk groups with significantly inferior outcomes. This review discusses recent updates in risk stratification and treatment approaches from upfront treatment for limited and advanced stage follicular lymphoma to the growing options for relapsed, refractory disease with perspectives on how to approach this from a personalized lens. Notable gaps remain on how one can precisely and prospectively select optimal treatment for patients based on varying risks, with an anticipation that an increased understanding of the biology of these different phenotypes and increasing refinement of imaging- and biomarker-based tools will, in time, allow these gaps to be closed.
